(Q44342429)

reason for preferred rank

2 December 2017

title

Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas (English)

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

25 October 2022

Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1672268

25 October 2022

1 reference

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

25 October 2022

author name string

L. Duranteau

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1672268

25 October 2022

P. Chanson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1672268

25 October 2022

A. Lavoinne

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1672268

25 October 2022

S. Horlait

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1672268

25 October 2022

J. Lubetzki

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1672268

25 October 2022

J. M. Kuhn

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1672268

25 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1672268

25 October 2022

publication date

1 January 1991

1 reference

full work available at URL

2 December 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2265.1991.tb01731.x

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2265.1991.tb01731.x/fullpdf

25 October 2022

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

25 October 2022

published in

Clinical Endocrinology

1 reference

2 December 2017

volume

34

1 reference

2 December 2017

issue

1

1 reference

2 December 2017

page(s)

25-29

1 reference

Galactorrhoea: Successful Treatment with Reduction of Plasma Prolactin Levels by Brom-ergocryptine

2 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

Failure of bromocriptine to maintain reduction in size of a macroprolactinoma.

25 October 2022

2

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study

25 October 2022

3

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

Size Reduction of Macroprolactinomas by Bromocriptine or Lisuride Treatment*

25 October 2022

4

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

3HSpiperone Binding to Human Anterior Pituitaries and Pituitary Adenomas Secreting Prolactin, Growth Hormone, and Adrenocorticotropic Hormone*

25 October 2022

5

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride

25 October 2022

6

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases

25 October 2022

7

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

Effects of bromocriptine on pituitary tumour size

25 October 2022

9

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study

25 October 2022

10

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

Resistance to bromocriptine in prolactinomas

25 October 2022

11

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia.

25 October 2022

12

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

Rapid regression of pituitary prolactinomas during bromocriptine treatment

25 October 2022

14

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

CV 205-502 treatment of hyperprolactinemia

25 October 2022

15

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

Bromocriptine in management of large pituitary tumours

25 October 2022

17

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

Treatment of patients with prolactinomas

25 October 2022

18

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB01731.X

25 October 2022

Identifiers

1 reference

2 December 2017

1 reference